Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19

Louis Kishfy; Marcel Casasola; Peymaan Banankhah; Arshi Parvez; Yu Jen Jan; Anant M Shenoy; Carey Thomson; Mahmoud A AbdelRazek

doi:10.1016/j.jns.2020.116943

Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19

J Neurol Sci. 2020 Jul 15:414:116943. doi: 10.1016/j.jns.2020.116943. Epub 2020 May 23.

Authors

Louis Kishfy¹, Marcel Casasola¹, Peymaan Banankhah¹, Arshi Parvez¹, Yu Jen Jan¹, Anant M Shenoy², Carey Thomson³, Mahmoud A AbdelRazek⁴

Affiliations

¹ Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.
² Division of Neurology, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.
³ Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA; Division of Pulmonary and Critical Care, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.
⁴ Division of Neurology, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA. Electronic address: mabdelrazek@mah.harvard.edu.

Abstract

•
PRES is potentially a complication of severe SARS-CoV-2 infection.
•
Consider PRES in COVID-19 patients with altered mentation.
•
Consider tight blood pressure control in ventilated patients with COVID-19.
•
Hypertensive encephalopathy may prolong ventilator times in COVID-19 patients.

Keywords: Hypertensive encephalopathy; PRES; Posterior reversible encephalopathy syndrome; Reversible posterior leukoencephalopathy syndrome; SARS-CoV-2; coronavirus disease 2019.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Arthritis, Juvenile*
Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Pandemics
Pneumonia, Viral
Posterior Leukoencephalopathy Syndrome*
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
tocilizumab